Initiating Coverage with an Outperform Rating. Prospects Beyond 2022 are Favorable.
With the acquisitions of Celgene in 2019 and MyoKardia in 2020, BMS has substantially transformed its business and repositioned for growth. Drugs added to the portfolio from the two acquisitions produced 40% of its total revenues in 2020. The company has launched six new products since 2020, including two CAR-T immunotherapies, a class of treatments that has produced miraculous responses in fighting blood cancers. It plans to launch two potential first-in-class treatments in 2022 that have good commercial potential. BMS also has a broad early-to-mid stage pipeline with more than 50 new compounds in clinical development.
Continue reading